scorecard
  1. Home
  2. tech
  3. news
  4. San Francisco startups have suspended sales of at-home coronavirus test kits after the FDA issued a warning

San Francisco startups have suspended sales of at-home coronavirus test kits after the FDA issued a warning

Avery Hartmans   

San Francisco startups have suspended sales of at-home coronavirus test kits after the FDA issued a warning
coronavirus test

Claudio Furlan/LaPresse via AP

  • San Francisco startups Nurx and Carbon Health have stopped offering at-home coronavirus testing kits.
  • Both startups suspended sales after the Food and Drug Administration issued a warning last week that it had not authorized testing for the virus at home.
  • As of March 20, the US had one of the $4 among developed countries.
  • $4.

Two San Francisco startups that had begun offering coronavirus home testing kits have suspended sales after a warning was issued from the Food and Drug Administration.

Both Carbon Health and Nurx have paused sales of the tests after $4 that it has not authorized any at-home testing for COVID-19, the disease caused by the novel coronavirus, according to $4

Carbon Health, a startup that offers primary and urgent care services, $4 that it would begin shipping at-home test kits for $167.50 to patients who qualified to request a kit, meaning patients who felt sick and had been told by a healthcare provider to stay at home.

Since the FDA issued its warning, Carbon Health is $4, but it does still offer coronavirus-related help, like the option to check your symptoms online, find a clinic to take a test in person, or chat virtually with a medical professional.

Nurx, a startup that offers birth control and STI and HIV testing, was selling COVID-19 test kits that could be overnighted to patients after they completed an evaluation that was reviewed by a Nurx provider. The company says on its website that it has $4.

Both test kits involved taking your own oral swab and sending it to a laboratory for testing.

Neither Nurx nor Carbon Health immediately responded to Business Insider's requests for comment.

Both startups and healthcare giants have started looking for ways to increase testing over the last several weeks in the wake of $4 in February. The new guidelines aim to speed up the approval process for labs in the US making COVID-19 tests, but the rules have caused confusion. $4: The FDA guidelines did not allow for at-home testing, but did allow for companies with tests that had already been approved to begin using them to test for the coronavirus. Some startups use labs that have been certified under specific quality-control standards, which are allowed to start performing coronavirus tests under the new rules.

The US has faced issues in getting more people tested, and as of March 20, the US had one of the $4 among developed countries. Additionally, the US is facing $4 that are used to run tests.

As of Tuesday, $4, and 17,159 people have died, including $4.

Digital Health Pro

Featured Digital Health Articles:
- Telehealth Industry: Benefits, Services & Examples
- Value-Based Care Model: Pay-for-Performance Healthcare
- Senior Care & Assisted Living Market Trends
- Smart Medical Devices: Wearable Tech in Healthcare
- AI in Healthcare
- Remote Patient Monitoring Industry: Devices & Market Trends

NOW WATCH: $4



Popular Right Now



Advertisement